Since 2019, the Kineticos Disruptor Fund Series has invested in bold science and visionary founders working to change the future of patient care.
Our areas of focus include breakthrough technologies for cancer, and neurodegenerative and rare diseases.
Investment Focus & ThesisOur team is driven by a shared mission: to help visionary founders build companies that improve patient outcomes. United by a shared vision, we partner with innovators to accelerate the development of disruptive technologies. With a hands-on approach and a proven track record, we work alongside founders to turn ambitious ideas into impactful, patient-centric businesses.
Learn MoreKineticos targets high-growth, innovation-driven markets. Across the Kineticos Disruptor Fund Series, we prioritize cutting-edge technologies and science-backed solutions that have the potential to transform patient care and redefine industry standards.
)
"The support from Kineticos Ventures and their network has been crucial for Inceptor Bio. Our Board members representing Kineticos Ventures are generous with their time and energy and consistently provide constructive, actionable feedback to our leadership team. We are grateful to have such truly invested investors!"Inceptor Bio | Management Team
)
"Since the early days of Promaxo, Kineticos has been an important ally. They have consistently focused on our needs and helped us advance our innovative modular MRI platform. Kineticos’ business and scientific acumen has resonated with our team."Promaxo | Dr. Amit Vohra | Founder & CEO
)
"We have appreciated the input from Kineticos as hands on and supportive investors. Frank and the team have been helpful in making introductions and leveraging their network."EnteroBiotix | Dr James McIlroy MBChB BMedSci (Hons) | CEO
)
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma…
Kineticos Portfolio Company Inceptor Bio Announces Strategic Partnership for Next-Generation Solid Tumor CAR-T December 18, 2024 –Inceptor Bio, a leading…
)
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials, Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowl…